Triciribine (NSC 154020)

Catalog No.S1117 Synonyms: VD-0002, vqd-002, API-2, TCN

For research use only.

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

Triciribine (NSC 154020) Chemical Structure

CAS No. 35943-35-2

Selleck's Triciribine (NSC 154020) has been cited by 36 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Other Akt Products

Biological Activity

Description Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Targets
HIV-1 [2]
(CEM-SS, H9, H9IIIB, U1 cells)
Akt [1]
(PC3 cells)
20 nM 130 nM
In vitro

Triciribine exhibits maximum growth inhibition around 1-10 μM and inhibits phosphorylation of Akt, as well as downstream p70S6K, to basal levels at 100μM (IC50 = 130 nM). Triciribine shows particular promise for inhibiting growth in Nf1 and Trp53 mutant astrocytoma cells in a grade-dependent manner. The WHO II K1861-10 line is inhibited, incompletely (69% maximum inhibition), with a GI50 value of 1.7 μM for Triciribine, whereas higher-grade tumor lines (KR158, KR130, and SF295) are inhibited to a greater extent (>80% maximum inhibition) at lower GI50 values (0.4–1.1 mM). Importantly, Triciribine is much less effective at inhibiting primary astrocytes (GI5013.6 mM), suggesting that this inhibitor may show specificity for tumor cells. [1] Triciribine inihibits HIV-1with an IC50 of 20 nM. Greater than 90% inhibition is achieved at 0.1μM and complete inhibition of syncytia formation is achieved at 5μM. Associated cell toxicity in the same cell line for Triciribine is 46 μM, resulting in selectivity indices of 2250. Triciribine markedly inhibits HIV-1-induced p24 core antigen production, reverse transcriptase, and infectious virus production in a dose-dependent manner using HIV-1 acutedly infected CEM-SS, H9, and persistently infected H9III B and U1 cells. [2] Triciribine inhibits Akt phosphorylation at Thr308 and Ser473 and Akt activity in the human prostate cancer cell line PC-3. Triciribine sensitizes PC-3 cells to TRAIL- and anti-CD95-induced apoptosis, whereas the cells remain resistant to DNA damaging chemotherapeutics. [3] Triciribine is highly selective for Akt and does not inhibit the activation of phosphatidylinositol 3-kinase, phosphoinositide-dependent kinase-1, protein kinase C, serum and glucocorticoid-inducible kinase, protein kinase A, signal transducer and activators of transcription 3, extracellular signal-regulated kinase-1/2, or c-Jun NH2-terminal kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 NX62O|VITnWwY4Tpc44h[XO|YYm= NXzsOmJtXGW|dHXkJIlvKH[rdILvJIZweiCleYTveI95cWOrdImgZYdicW6|dDDteZJqdmViTEGyNVAhdGW3a3XtbYMh[2WubIOsJGlEPTB;MD6wN|XPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh6MkO3NUc,OTB6OEKzO|E9N2F-
HFF M4TGZ2Z2dmO2aX;uJIF{e2G7 M2H5TGhEVVZicHzhdZVmKGG|c3H5JJdieyCyZYLmc5Ju\WRidYPpcochUE[IIHPlcIx{KGGwZDDl[oZm[3Rid3HzJINidGO3bHH0[YQh[XNiYTDw[ZJk\W62YXflJI9nKHKnZIXjeIlwdiCrbjDueY1j\XJib3[gdIxieXWnczygTWM2OD1{LkZOwG0> MnflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6OEKzO|EoRjFyOEiyN|cyRC:jPh?=
BSC-1 MlLHRY51cX[rcnHsJIF{e2G7 M4L0SmFvfGm4aYLhcEBi[3Srdnn0fUB4[XNidHXzeIVlKHW|aX7nJIFvKGWweont[U1tcW6tZXSgbY1ufW6xc3;yZoVvfCCjc4PhfUApTUyLU1GpJJRwKGSndHXjeEBJW1ZvMTCobIVzeGW|IIPpcZBt\XhidnnyeZMhfHmyZTCxLUB2e2mwZzDCV2MuOSClZXzsd{whUUN3ME2yN:69VQ>? NYr4fYxQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4PFI{PzFpPkGwPFgzOzdzPD;hQi=>
HFF MVjBcpRqfmm{YXygZZN{[Xl? MlTWRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGNOXiC5YYOg[IV1\XKvaX7l[EBjgSCybHHxeYUhemWmdXP0bY9vKGG|c3H5JJV{cW6pIFjGSkBk\WyuczygTWM2OD1{LkZOwG0> M{CyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOEiyN|c{Lz5zMEi4NlM4OzxxYU6=
AA2 M1zyXmZ2dmO2aX;uJIF{e2G7 MkjUOUBpenN? NFKzZ4JKdnS{YXPlcIx2dGG{IIDoc5NxcG:{eXzheIlwdiBqMUCwJJVOMSCrbjD1colv\mWldHXkJGFCOiClZXzsd{B4[XNic4T1[Ilm\CCjZoTldkA2KGi{czDv[kBKdmO3YnH0bY9vNixiQ3;uZ4VvfHKjdHnvcl06|ryP NUjy[5Z6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4PFI{PzNpPkGwPFgzOzd|PD;hQi=>
BSC-1 Mmq1RY51cX[rcnHsJIF{e2G7 NVrw[GJUSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUFOYLUGge4F{KGSndHXycYlv\WRidYPpcochSlOFLUGgZ4VtdHNiYomgZY4h\W68eX3lMYxqdmunZDDpcY12dm:|b4Li[Y51KGG|c3H5JEhGVEmVQTmsJGlEPTB;MkROwG0> M3nRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOEiyN|c{Lz5zMEi4NlM4OzxxYU6=
Huh-7 NHLBRYVHfW6ldHnvckBie3OjeR?= MmrrR49ueG:3bnSge4F{KHSnc4Tl[EBnd3JiaYTzJIFjcWyrdImgeI8hcW6qaXLpeEBp\XCjdHn0bZMhSyC4aYLhcEBTVkFicnXwcIlk[XSrb36gbY4hUHWqLUegZ4VtdHNiKHj1cYFvKGincHH0c41iKGOnbHzzLUwhTUN3ME2y{txO M4nTRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUe3OFY1Lz5zNUG3O|Q3PDxxYU6=
MCF7 NFfveFZEgXSxdH;4bYNqfHliYYPzZZk> MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2wMlA2|ryP MnTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MCF7 MkfnR5l1d3SxeHnjbZR6KGG|c3H5 M{PCWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPTcQvF2= MmHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MDA-MB-231 MkiwR5l1d3SxeHnjbZR6KGG|c3H5 MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD1yLk[5{txO Ml;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MCF7 Mn;MR5l1d3SxeHnjbZR6KGG|c3H5 MmDIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Oy54NN88US=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
MDA-MB-468 NIiwPZZEgXSxdH;4bYNqfHliYYPzZZk> MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD1zMD6yPe69VQ>? MljtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
184B5 MVHDfZRwfG:6aXPpeJkh[XO|YYm= NVfNRnhuOjBidV2= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxPFRDPSClZXzsd{BifCB{MDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;MU[uPVbPxE1? NHjNWYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-468 NXfmfpcyS3m2b4TvfIlkcXS7IHHzd4F6 NVfae25uOTBidV2= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD1{MD60Oe69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
184B5 NGLWUmdEgXSxdH;4bYNqfHliYYPzZZk> MoDJNVAhfU1? NYjOPG1NS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYYSgNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVM1|ryP MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MDA-MB-231 NIPFNGJEgXSxdH;4bYNqfHliYYPzZZk> NFnUNWEyOCC3TR?= NYXuS20yS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9N|fPxE1? NV3qTnkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
184B5 MUXDfZRwfG:6aXPpeJkh[XO|YYm= MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxPFRDPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:PDEQvF2= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
MDA-MB-468 MlL3R5l1d3SxeHnjbZR6KGG|c3H5 NXHwUIVES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:PDNwNUROwG0> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
MDM MXXBcpRqfmm{YXygZZN{[Xl? MmL2OkBl[Xm| NVi3cos6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIFHERUBqdm[nY4Tl[EBqdiCqdX3hckBOTE1iY3XscJMh[XO|ZYPz[YQh[XNiZYjwdoV{e2mxbjDv[kBxOjRiYX70bYdmdiCjZoTldkA3KGSjeYOgdI9{fGmwZnXjeIlwdiCkeTDFUGlUSSxiSVO1NF0xNjByNt88US=> NX\FU3lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
ACH2 NF3LfnFEgXSxdH;4bYNqfHliYYPzZZk> MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBR2gzKGOnbHzzJIlv\mWldHXkJJdqfGhibHH0[Y51KEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTDifUBOXFNiYYPzZZktKEOFNUC9NE4xOc7:TR?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
ACH2 MlXPR5l1d3SxeHnjbZR6KGG|c3H5 NUnm[|ZkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSUOKMjDj[YxteyCrbn\lZ5Rm\CC5aYToJIxifGWwdDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEh[nliTWTTJIF{e2G7IHnuJJBz\XOnbnPlJI9nKHS3bX;yJI5m[3Kxc3nzJIZi[3SxcjDhcJBp[SxiQ1O1NF0xNjBzzszN NHHLVog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS MlX5RY51cX[rcnHsJIF{e2G7 NF\PeGk3KGSjeYO= MUjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMD63PEB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCneIDy[ZN{cW:wIH;mJJAzPCCjboTp[4VvKGGodHXyJFYh\GG7czDwc5N1cW6oZXP0bY9vKGK7IFXMTXNCNCCLQ{WwQFAvODIQvF2= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
MDM MVvBcpRqfmm{YXygZZN{[Xl? NU\NWmZkPiCmYYnz NULCO|lpSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIFLBUEBqdm[nY4Tl[EBqdiCqdX3hckBOTE1iY3XscJMh[XO|ZYPz[YQh[XNiZYjwdoV{e2mxbjDv[kBxOjRiYX70bYdmdiCjZoTldkA3KGSjeYOgdI9{fGmwZnXjeIlwdiCkeTDFUGlUSSxiSVO1NF0xNjBzON88US=> NXvJcVB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
H9 MoPNRY51cX[rcnHsJIF{e2G7 NIf2cphCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiU1uxJIlv\mWldHXkJIlvKGi3bXHuJGg6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIJ6KFt|SG3UWHAhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NF0xNjB|Nt88US=> M{fwSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NVnVVoJwSW62aY\pdoFtKGG|c3H5 MXrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiZYjwdoV{e2mwZzDu[YYheHKxdHXpckBqdm[nY4TpcochcW5iQ1XNMXNUKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIJ6KFt|SG3UWHAhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NF0xNjB2zszN NXHldplYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
CEM-SS MU\BcpRqfmm{YXygZZN{[Xl? MYPBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMD63PEB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5yON88US=> NXf0SmJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
H9 MkTyRY51cX[rcnHsJIF{e2G7 M1;hNWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDIPUBk\WyuczDpcoZm[3SnZDD3bZRpKDJ3IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlHPxE1? MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 M{fMS2FvfGm4aYLhcEBie3OjeR?= Moq3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFi5JINmdGy|IHnu[oVkfGWmIIfpeIghOTJwNTD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4y|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 MoPURY51cX[rcnHsJIF{e2G7 MWnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEA3NjJ3IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlHPxE1? M1\ES|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 NFPJdYpCdnSrdnnyZYwh[XO|YYm= MmLWOkBl[Xm| MonmRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFi5JINmdGy|IHnu[oVkfGWmIIfpeIghOTJwNTD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BmgHC{ZYPzbY9vKG:oIICyOEBidnSrZ3XuJIFnfGW{IE[g[IF6eyCyb4P0bY5n\WO2aX;uJIJ6KEWOSWPBMEBKSzVyPECuNe69VQ>? M1j6eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 MlO2RY51cX[rcnHsJIF{e2G7 MmToOkBl[Xm| NUm3cnZFSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGg6KGOnbHzzJIlv\mWldHXkJJdqfGhiNj6yOUB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCneIDy[ZN{cW:wIH;mJJAzPCCjboTp[4VvKGGodHXyJFYh\GG7czDwc5N1cW6oZXP0bY9vKGK7IFXMTXNCNCCLQ{WwQFAvOc7:TR?= NGX6eIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS MUPBcpRqfmm{YXygZZN{[Xl? MnGyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKFONMTDpcoZm[3SnZDDpckBpfW2jbjDDSW0uW1NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDS[ZZmenOnIITyZY5{[3KrcIThd4Uh[nliW{PIYXRVWCCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR|UxRTBwMUROwG0> NVznRWpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
ACH2 NH7HVZpCdnSrdnnyZYwh[XO|YYm= NIHT[VU{KGSjeYO= M3H6RWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JFUhgCBzMDezJINmdGy|L4flcIwhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHnu[oVkfGWmIHnuJIh2dWGwIFHDTFIh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCCUZY\ldpNmKHS{YX7zZ5JqeHSjc3WgZYZ1\XJiMzDkZZl{KGK7IGuzTH1VXFBiaX7jc5Jxd3KjdHnvckBie3OjeTDpckBxemW|ZX7j[UBw\iB3IH7nM41tKHS3bX;yJI5m[3Kxc3nzJIZi[3SxcjDhcJBp[SxiSVO1NF0xNjF3zszN NWnCRmJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
AA5 MnvWRY51cX[rcnHsJIF{e2G7 MVXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDv[kBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hSUF3IHPlcIx{KGmwZnXjeIVlKHerdHigN{4yOyC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB:MD6xO:69VQ>? MmTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
AA5 NFXZdYVCdnSrdnnyZYwh[XO|YYm= NITNbpRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBw\iCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgN2IhcW6oZXP0[YQhcW5iQVG1JINmdGy|IHnu[oVkfGWmIIfpeIghOS53NjD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4yP87:TR?= NFPqXZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
AA5 NIHZO4hCdnSrdnnyZYwh[XO|YYm= M{PLdmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JI9nKEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTCzRkBqdm[nY4Tl[EBqdiCDQUWgZ4VtdHNiaX7m[YN1\WRid3n0bEAxNjd6IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlE4|ryP MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS M2DZR2FvfGm4aYLhcEBie3OjeR?= MVm2JIRigXN? NXy4PGhxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGNGVS2VUzDj[YxteyCrbn\lZ5Rm\CC5aYToJFEvPTZidVygc4Yhfmm{dYOgd5Rw[2tiYYPz[ZN{\WRiYYOg[ZhxemW|c3nvckBw\iCyMkSgZY51cWenbjDh[pRmeiB4IHThfZMheG:|dHnu[oVkfGmxbjDifUBGVEmVQTygTWM2OD1yLkG5{txO M1nOelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NYH5fmQ3SW62aY\pdoFtKGG|c3H5 NH\lXI9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaHHyZo9zcW6pIIDsZZNucWRiTly0MVMhcW6oZXP0[YQhcW5iQ1XNMXNUKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIJ6KFt|SG3UWHAhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NF0xNjMQvF2= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
U1 NGjqfFlCdnSrdnnyZYwh[XO|YYm= MXvBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhcW6oZXP0[YQhcW5iaIXtZY4hXTFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDS[ZZmenOnIITyZY5{[3KrcIThd4Uh[nliW{PIYXRVWCCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR|UxRTBwMkROwG0> NUDrUGY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
CEM-SS MorlRY51cX[rcnHsJIF{e2G7 MlixOkBl[Xm| NG\qR2dCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigN{4yOyC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDlfJBz\XO|aX;uJI9nKHB{NDDhcpRq\2WwIHHmeIVzKDZiZHH5d{Bxd3O2aX7m[YN1cW:wIHL5JGVNUVODLDDJR|UxRTBwMkVOwG0> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
U1 NVzHSmJqS3m2b4TvfIlkcXS7IHHzd4F6 MnfYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVEh[2WubIOgbY5n\WO2ZXSge4l1cCCuYYTlcpQhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHL5JG1VWyCjc4PhfUwhS0N3ME2wMlI5|ryP Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
U1 MXvDfZRwfG:6aXPpeJkh[XO|YYm= M1XUbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHUyKGOnbHzzJIlv\mWldHXkJJdqfGhibHH0[Y51KEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTDifUBOXFNiYYPzZZkhcW5icILld4Vv[2Vib3[geJVud3JibnXjdo9{cXNiZnHjeI9zKGGucHjhMEBESzVyPUCuNljPxE1? NHKzWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS MVXBcpRqfmm{YXygZZN{[Xl? NGfa[phCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigNU42PiC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD6yPe69VQ>? Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
CEM-SS MX3BcpRqfmm{YXygZZN{[Xl? MUTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMz6xN{B2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5|zszN NVjtRlhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
CEM-SS NV7aO5pmSW62aY\pdoFtKGG|c3H5 MXjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhTDFiaHHyZo9zcW6pIGT5dlEzP0irczDteZRifGmxbjDpckBv\WZicILveIVqdiCrbn\lZ5RqdmdiaX6gR2VONVOVIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygVoV3\XK|ZTD0doFve2O{aYD0ZZNmKGK7IGuzTH1VXFBiaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OD1yLkOz{txO M1fjdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NFvkTXdCdnSrdnnyZYwh[XO|YYm= M3;1ZWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCDNzDoZZJjd3KrbnegWJlzOTJ5SHnzJI12fGG2aX;uJIlvKG6nZjDwdo91\WmwIHnu[oVkfGmwZzDpckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUCuOe69VQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
MDM MVzDfZRwfG:6aXPpeJkh[XO|YYm= NH3iVW5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTE1iY3XscJMhcW6oZXP0[YQhf2m2aDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhSkGOIHL5JG1VWyCjc4PhfUwhXEN3ME2wMlY3|ryP MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS NUfnPYhbSW62aY\pdoFtKGG|c3H5 NETnNWtCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDJiUl;EJIlv\mWldHXkJIlvKGi3bXHuJGNGVS2VUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MT60{txO NUna[FJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
H9 NFPrUmVCdnSrdnnyZYwh[XO|YYm= MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEA2OCC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MT61N:69VQ>? NHvMW|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
H9 NWL1eGM2S3m2b4TvfIlkcXS7IHHzd4F6 NHOyd3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJQSClZXzsd{BjgSCPVGOgZZN{[XluIFnDOVA:OTZwM988US=> M3Tx[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 NIL0bVZEgXSxdH;4bYNqfHliYYPzZZk> MmDMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFkh[2WubIOgZpkhVVSVIHHzd4F6NCCFQ{WwQVE6NjcQvF2= NVm1WHZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
Assay
Methods Test Index PMID
Western blot PUMA / p-FoxO3a / p-AKT 20978166
Immunofluorescence TRF2 / 53BP1 23862686
In vivo 1 mg/kg/day i.p. treated Triciribine inhibits OVCAR3, OVCAR8 and PANC1 tumor growth, which overexpressing Akt, by 90%, 88% and 80% in nude mice, respectively. However, Triciribine has little effect on the growth of OVCAR5 and COLO357 cells. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Akt Phosphorylation Changes Assay:

    Cells are grown to 80%–90% confluency and stimulated for 5–10 minutes with 1–10 ng/mL of epidermal growth factor or platelet derived growth factor (PDGF)–AA with or without 10–20 mM of U0126 or LY-294002. Protein lysates (5–20 μg) are separated by 12%–15% SDS PAGE and analyzed by Western blot for Akt, phosphorylated Akt (phospho-Ser 473), MAPK, and phosphorylated MAPK (p44/42 phospho-Thr202/Tyr204) antibodies (1:1000).

Cell Research:[2]
  • Cell lines: CEM-SS cells
  • Concentrations: 0-500 μM
  • Incubation Time: 48 hours
  • Method: Triciribine is evaluated for cytotoxicity by seeding CEM-SS cells at a density of 1 × 104 cells/well in growth medium, using a 96-well flat-bottom plate. Serial fivefold dilutions of Triciribine are prepared in growth medium and added to the wells as a second overlay. After a 48-hours incubation at 37 °C, the cells are pulse labeled with [3H]dThd (1 μCi per well, specific activity 20 Ci/mmol) for 6 hours and the cells are harvested to measure total DNA synthesis.
Animal Research:[4]
  • Animal Models: OVCAR3, OVCAR8, PANC1, OVCAR5 and COLO357 tumor cells are injected s.c. into 80week-old female nude mice.
  • Dosages: 1 mg/kg/day
  • Administration: Triciribine is administrated through i.p. injection once a day.

Solubility (25°C)

In vitro

DMSO 64 mg/mL
(199.81 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 320.3
Formula

C13H16N6O4

CAS No. 35943-35-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C2=NC=NC3=C2C(=CN3C4C(C(C(O4)CO)O)O)C(=N1)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02987127 Unknown status -- Mucosa-Associated Lymphoid Tissue Lymphoma National Taiwan University Hospital February 2016 --
NCT00642031 Completed Drug: Triciribine Hematologic Malignancies|Leukemia Prescient Therapeutics Ltd.|VioQuest Pharmaceuticals August 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Triciribine (NSC 154020) | Triciribine (NSC 154020) supplier | purchase Triciribine (NSC 154020) | Triciribine (NSC 154020) cost | Triciribine (NSC 154020) manufacturer | order Triciribine (NSC 154020) | Triciribine (NSC 154020) distributor